The calcimimetic etelcalcetide attenuates pressure overload–induced cardiac hypertrophy in rats with and without chronic kidney disease
ET effectively suppressed LVH in the LVH and CKD/LVH groups. These findings suggest that ET's cardioprotective effects are mediated via the modulation of the RAAS and cardiac FGF23 expression rather than solely through the correction of CKD-mineral bone disorder abnormalities.
Authors
- Hayaki Okamoto
- Shunsuke Goto (ORCID: https://orcid.org/0000-0002-7102-2843)
- Hideki Fujii (ORCID: https://orcid.org/0000-0001-7923-4165)
- Yuma Nose
- Hidehisa Okamoto
Institutions
- Kobe University (JP)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1016/j.biopha.2026.119054
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00